A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes.

ABSTRACT:

Context

There is a medical need for effective insulin-independent antidiabetic drugs that can promote pancreatic β-cell function and have a low risk of hypoglycemia in type 2 diabetes mellitus (T2DM) patients. R-form verapamil (R-Vera), which is able to enhance the survival of β-cells and has higher cardiovascular safety margin compared with racemic verapamil, was developed as a novel approach for T2DM treatment.

Objective

This randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of 3 dosages of R-Vera added to ongoing metformin therapy in T2DM patients who had inadequate glycemic control on metformin alone.

Methods

Participants were randomly assigned in an equal ratio to receive R-Vera 450, 300, or 150 mg per da

SUBMITTER: Wang CY 

PROVIDER: S-EPMC9516171 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature